Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease: JACC Scientific Statement

Authors

Daniel E Forman
George A Kuchel
John C Newman
James L Kirkland
Elena Volpi
George E Taffet
Nir Barzilai
Ambarish Pandey
Dalane W Kitzman
Peter Libby
Luigi Ferrucci

Publication Date

8-15-2023

Journal

Journal of the American College of Cardiology

DOI

10.1016/j.jacc.2023.05.038

PMID

37389519

PMCID

PMC10414756

PubMedCentral® Posted Date

8-15-2024

PubMedCentral® Full Text Version

Author MSS

Published Open-Access

yes

Keywords

Aged, Humans, Aging, Cardiovascular Diseases, Chronic Disease, Frailty, Geriatrics, Geroscience, frailty, geroscience, hallmarks, inflammation, multimorbidity

Abstract

Geroscience posits that cardiovascular disease (CVD) and other chronic diseases result from progressive erosion of the effectiveness of homeostatic mechanisms that oppose age-related accumulation of molecular damage. This hypothetical common root to chronic diseases explains why patients with CVD are often affected by multimorbidity and frailty and why older age negatively affects CVD prognosis and treatment response. Gerotherapeutics enhance resilience mechanisms that counter age-related molecular damage to prevent chronic diseases, frailty, and disability, thereby extending healthspan. Here, we describe the main resilience mechanisms of mammalian aging, with a focus on how they can affect CVD pathophysiology. We next present novel gerotherapeutic approaches, some of which are already used in management of CVD, and explore their potential to transform care and management of CVD. The geroscience paradigm is gaining traction broadly in medical specialties, with potential to mitigate premature aging, reduce health care disparities, and improve population healthspan.

Comments

Associated Data